Peptide profile · Hormone Support
Nafarelin
A potent GnRH agonist that initially stimulates then suppresses reproductive hormones, used for treating endometriosis and central precocious puberty with convenient nasal spray delivery.
Molecular formula
C66H83N17O13
- CAS number
- 86220-42-0
- PubChem
- 25077405
- Developed · 1988
- Searle/Pharmacia Research Team, Searle (later Pharmacia/Pfizer)
Amino acid sequence
pGlu-His-Trp-Ser-Tyr-D-2-Nal-Leu-Arg-Pro-Gly-NH2400 – 1,800mcg/day
Every documented dose level
| Phase | Dose | Frequency |
|---|---|---|
| 6 months | 400 mcg/day (one 200 mcg spray each nostril, AM and PM) | Twice daily |
| Until resumption of puberty is desired | 1600-1800 mcg/day (400 mcg per nostril dosing) | Twice daily (up to 3 times) |
Best for managing moderate to severe endometriosis pain that doesn't respond to other treatments & treating children with precocious puberty (early puberty)
Best for
Managing moderate to severe endometriosis pain that doesn't respond to other treatments
Nafarelin is particularly well-suited for individuals focused on managing moderate to severe endometriosis pain that doesn't respond to other treatments. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Treating children with precocious puberty (early puberty)
Nafarelin is particularly well-suited for individuals focused on treating children with precocious puberty (early puberty). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Preparing women for endometriosis surgery by reducing inflammation
Nafarelin is particularly well-suited for individuals focused on preparing women for endometriosis surgery by reducing inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Improving fertility outcomes in assisted reproductive procedures
Nafarelin is particularly well-suited for individuals focused on improving fertility outcomes in assisted reproductive procedures. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider alternatives if
Do not use if
- Pregnancy (can harm fetus - must use non-hormonal birth control)
- Hypersensitivity to GnRH agonists
- Undiagnosed vaginal bleeding
- Severe osteoporosis or bone disease
Use with caution if
- You are taking other medications—discuss potential interactions with your healthcare provider
- You have a history of liver or kidney disease
- You are elderly or have multiple medical conditions
- You are planning surgery in the near future—inform your surgeon about Nafarelin use
- You have any chronic health conditions that require regular monitoring
Not sure?
Compare Nafarelin with similar peptides to find the best fit for your goals.
Route
Subcutaneous injection (into the fatty tissue just under the skin)—allows for consistent absorption and can be self-administered at home after proper training
Best sites
- Abdomen (stomach area)—at least 2 inches from the belly button, most popular choice for self-injection
- Front of thighs—middle to upper portion of the outer leg
- Back of upper arm—outer area (may need assistance from another person)
The Nafarelin dosing protocol covers how it is taken.
30 common side effects · 2 serious
Nafarelin is FDA-approved with a well-established safety profile across decades of clinical use for endometriosis and precocious puberty.
The most significant safety consideration is hypogonadism and bone density loss during prolonged therapy, requiring add-back therapy (norethindrone 0.4 mg daily) after 6 months to prevent osteoporosis.
Common side effects—hot flashes, vaginal dryness, mood changes—are reversible upon discontinuation and typically diminish with continued use.
FDA approval based on multiple randomized controlled trials in endometriosis (n=1000+) showing superior efficacy versus danazol with improved tolerability.
Long-term safety data from 20+ years of clinical use demonstrates Class III osteoporosis risk after 12 months without add-back therapy, measured via DEXA scans. Cardiovascular effects minimal; lipid profile changes are modest and reversible.
Common side effects · experienced by some users
Hot flashes and night sweats (happen in 90% of users)
Hot flashes and night sweats (happen in 90% of users)
Management
Consult your healthcare provider for guidance.
Mood changes including depression or anxiety
Mood changes including depression or anxiety
Management
Consult your healthcare provider for guidance.
Decreased sexual interest
Decreased sexual interest
Management
Consult your healthcare provider for guidance.
Vaginal dryness
Vaginal dryness
Management
Consult your healthcare provider for guidance.
Headaches
Headaches
Management
Consult your healthcare provider for guidance.
Nasal irritation (if using spray formulation)
Nasal irritation (if using spray formulation)
Management
Consult your healthcare provider for guidance.
Breast tenderness
Breast tenderness
Management
Consult your healthcare provider for guidance.
Muscle aches and joint pain
Muscle aches and joint pain
Management
Consult your healthcare provider for guidance.
Weight gain or changes in body composition
Weight gain or changes in body composition
Management
Consult your healthcare provider for guidance.
Nausea and upset stomach
Nausea and upset stomach
Management
Consult your healthcare provider for guidance.
Sleep problems
Sleep problems
Management
Consult your healthcare provider for guidance.
Emotional sensitivity and mood swings
Emotional sensitivity and mood swings
Management
Consult your healthcare provider for guidance.
Allergic reactions (rare)
Allergic reactions (rare)
Management
Consult your healthcare provider for guidance.
Significant bone density loss with extended use
Significant bone density loss with extended use
Management
Consult your healthcare provider for guidance.
Severe mood disorders requiring medical attention
Severe mood disorders requiring medical attention
Management
Consult your healthcare provider for guidance.
Hot flashes (flushes of heat and redness)
Hot flashes (flushes of heat and redness)
Management
Consult your healthcare provider for guidance.
Night sweats and chills
Night sweats and chills
Management
Consult your healthcare provider for guidance.
Vaginal dryness and discomfort
Vaginal dryness and discomfort
Management
Consult your healthcare provider for guidance.
Mood depression or anxiety
Mood depression or anxiety
Management
Consult your healthcare provider for guidance.
Changes in sexual desire
Changes in sexual desire
Management
Consult your healthcare provider for guidance.
Weight changes
Weight changes
Management
Consult your healthcare provider for guidance.
Headaches
Headaches
Management
Consult your healthcare provider for guidance.
Muscle and joint aches
Muscle and joint aches
Management
Consult your healthcare provider for guidance.
Nasal irritation or sinus problems
Nasal irritation or sinus problems
Management
Consult your healthcare provider for guidance.
Breast tenderness or swelling
Breast tenderness or swelling
Management
Consult your healthcare provider for guidance.
Acne
Acne
Management
Consult your healthcare provider for guidance.
Sleep disturbances
Sleep disturbances
Management
Consult your healthcare provider for guidance.
Nausea
Nausea
Management
Consult your healthcare provider for guidance.
Fatigue
Fatigue
Management
Consult your healthcare provider for guidance.
Bone pain
Bone pain
Management
Consult your healthcare provider for guidance.
Serious side effects
Severe allergic reaction
In rare cases, Nafarelin may trigger a severe allergic reaction including difficulty breathing, facial swelling, or widespread rash. This requires immediate medical attention.
Management
STOP treatment immediately and seek emergency medical care. Do not restart without medical clearance. Report all allergic reactions to your healthcare provider.
Stop and seek help if
- Severe or worsening side effects that don't improve with dose adjustment or supportive care
- Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- Your healthcare provider recommends discontinuation based on your clinical response
- Development of any new medical condition that may be contraindicated with Nafarelin
- Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- Abnormal lab results or clinical markers that suggest adverse effects
Nafarelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
With medications
- SafeBlood thinners (warfarin, heparin) — Monitor closely if combining with Nafarelin as interactions may affect bleeding risk or drug metabolism.
With supplements
- SafeMultivitamins — Generally safe to take alongside Nafarelin. Space doses apart if taking oral formulations to ensure optimal absorption.
- SafeElectrolyte supplements — Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Strong human trials · first signs days 1-3
Evidence level
Strong human trials
(Phase 3 or FDA approved)
100/100
Regulatory status
FDA approved for this use
Onset of effects
Moderate
(1-2 weeks)
How it works
Nafarelin is a GnRH agonist that tricks your pituitary gland into shutting down estrogen and testosterone production.
For endometriosis, lower estrogen means less tissue growth and pain. For early puberty in kids, lower hormones slow sexual development. The nasal spray makes it convenient—just a couple of sprays twice a day instead of daily injections.
The deeper mechanism
Nafarelin is a synthetic GnRH agonist decapeptide with D-2-naphthylalanine substitution at position 6 and N-terminal pyroglutamation that provides enhanced receptor binding and resistance to enzymatic degradation.
Upon administration (intranasal), nafarelin binds pituitary GnRH receptors with high affinity, initially causing acute FSH and LH release (flare phase, 7-14 days). Continuous nafarelin exposure leads to receptor desensitization and downregulation, suppressing gonadotropin secretion below baseline.
In women, this reduces estrogen production; in children with precocious puberty, it suppresses the pubertal hormone axis. The intranasal route provides convenient non-injectable delivery with approximately 2-3% bioavailability, enabling twice-daily dosing.
Estrogen suppression of 90%+ is achieved within 3-4 weeks, maintaining suppression throughout treatment duration.
What to expect
Days 1-3
What you might notice
- Initial injection flare - hormone levels spike briefly before dropping
- Some patients experience temporary worsening of symptoms
- Pituitary begins responding to the medication
What's normal
- Initial response to Nafarelin is beginning at the cellular level
- Different individuals experience Nafarelin's onset at different rates
- Transient systemic effects from initial Nafarelin exposure are common
What's next
- Maintain consistent Nafarelin administration as prescribed
- Document subjective effects and physical markers daily
- Schedule a check-in with your provider about initial observations
Weeks 1-2
What you might notice
- Hot flashes and night sweats typically begin
- Hormone suppression starts becoming noticeable
- Women may begin experiencing menopause-like symptoms
What's normal
- Nafarelin has achieved stable, long-term homeostatic integration
- Sustained efficacy of Nafarelin remains consistent
- Chronic Nafarelin effects remain stable and predictable
What's next
- Maintain your established Nafarelin protocol for sustained benefits
- Continue periodic monitoring to confirm Nafarelin efficacy
- Review comprehensive Nafarelin response with your provider
Weeks 3-4
What you might notice
- Significant hormone level suppression achieved
- Endometrial lesions begin shrinking
- Pain levels often start improving noticeably
What's normal
- Nafarelin is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Nafarelin's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Nafarelin dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Weeks 4-8
What you might notice
- Maximum symptom improvement usually reached
- Pain relief becomes significant
- Menstrual-like symptoms typically stop
What's normal
- Nafarelin is now achieving steady-state pharmacokinetics
- Measurable changes aligned with Nafarelin's mechanism may appear
- Initial adjustment effects typically resolve by this point
What's next
- Maintain Nafarelin dosing exactly as established
- Track progress toward intended outcomes in detail
- Review lab work or biomarker changes with your healthcare team
Months 3-6
What you might notice
- Peak therapeutic benefit maintained
- Endometrial lesions significantly smaller
- Patients report major quality-of-life improvements
What's normal
- Nafarelin has achieved stable, long-term homeostatic integration
- Sustained efficacy of Nafarelin remains consistent
- Chronic Nafarelin effects remain stable and predictable
What's next
- Maintain your established Nafarelin protocol for sustained benefits
- Continue periodic monitoring to confirm Nafarelin efficacy
- Review comprehensive Nafarelin response with your provider
After Stopping Treatment
What you might notice
- Pituitary function gradually returns to normal over several weeks
- Menstrual cycles and hormone levels restart
- Fertility typically returns within 3 months
What's normal
- Full therapeutic effects of Nafarelin are well-characterized at this point
- Maintenance of Nafarelin's therapeutic effects is typical
- Tolerance patterns with Nafarelin are generally stable over months
What's next
- Comprehensive assessment of Nafarelin efficacy should be conducted
- Discuss long-term continuation, cycling, or protocol modifications
- Continue regular monitoring of relevant biomarkers or symptoms
Signs it's working
Treatment Response
- Improvement in the primary symptoms or condition being treated
- Positive changes in relevant lab values or clinical markers
- Consistent, stable response to Nafarelin over time
- Reduction in symptom frequency or severity
Signs it's working
General Well-being
- Improved energy levels and daily functioning
- Better quality of life related to the treated condition
- Manageable or absent side effects indicating good tolerance
- Positive feedback from healthcare provider during check-ups
Not seeing results?
Common reasons
- Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- Insufficient time at target dose—most compounds need several weeks to show full benefits
- Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- Individual variation in response—genetics, metabolism, and other factors affect outcomes
- Underlying conditions or medications interfering with absorption or effectiveness
- Improper storage leading to degraded product—always verify proper storage conditions
11 registered studies, 3 still enrolling.
By phase
A trial spanning two phases is counted in both, so these can sum above the total. Observational studies carry no phase.
What kind of research
About 1,966 people took part in the studies that actually administered Nafarelin. Observational studies analyse the records of people already taking it — nobody was given anything for the study, so they are counted separately and cannot show cause and effect.
Most recent
Intranasal Nafarelin For Triggering Oocyte Maturation
Fundacion Dexeus
GnRH for Luteal Support - Mechanism of Action
Heli Alexandroni
Comparison of Pregnancy Rates in Modified Natural Frozen Embryo Transfer (FET) Cycle After Luteal Support with GnRH Agonist Versus Progesterone
Shaare Zedek Medical Center
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered twice is counted once. A study is counted when Nafarelin is named as an intervention; studies that only mention it in passing are not.
How quickly does Nafarelin work for endometriosis pain?
Pain relief is usually noticeable within 3-4 weeks, with maximum benefit by 8 weeks. Some people feel improvement within the first 2 weeks, while others take longer. The hot flashes and night sweats start almost immediately though, sometimes within days.
Will I get my period back after stopping Nafarelin?
Yes! Your menstrual cycle almost always returns within 1-3 months after finishing treatment. Your fertility typically returns at the same time. This is one of the biggest advantages over surgical treatment - your body goes back to normal.
Can I get pregnant while using Nafarelin?
No - Nafarelin suppresses your reproductive hormones, which prevents pregnancy. You must use non-hormonal birth control (like condoms) during treatment. Once you stop the medication, you can try to get pregnant whenever you're ready, as fertility usually returns quickly.
How bad are the hot flashes really?
They vary by person. Some people have mild warmth a few times daily, while others experience intense sweating and flushing many times per day. Most people find them manageable but uncomfortable. The good news is they usually improve after the first month and stop completely once you finish treatment.
Can I use Nafarelin for more than 6 months?
Most doctors limit continuous use to 6 months because of bone loss concerns. However, some doctors may recommend 12 months in severe cases, usually with add-back hormone therapy to protect your bones. Extended use is typically reserved for situations where the benefit really outweighs the risks.
What happens if I miss a dose?
Try to take it as soon as you remember, but skip it if it's almost time for your next dose. Don't double up on doses. Missing one or two doses occasionally won't ruin your treatment, but consistency is important for best results.
Is Nafarelin safe for teenagers with precocious puberty?
Yes, it's one of the standard treatments for precocious puberty in children and teenagers. The dosing is adjusted for body weight, and doctors monitor growth and development closely. It can help prevent adult height loss and other complications from early puberty.
Ready for the protocol?
Every dosing tier, administration route, timing note, and dose-adjustment rule for Nafarelin, on one page.
Nafarelin dosing protocol